Enlivex Receives Nasdaq Delisting Notice and Intends to Appeal
Enlivex Ltd. announced it received a delisting notification from Nasdaq due to its share price falling below the minimum bid requirement and plans to appeal the decision.
Stocks · News reference
Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trialWorkforce reduced by approximately 60%; management and CEO salaries reducedPlan designed to substantially reduce
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Enlivex Announces 1-for-16 Reverse Stock Split
Enlivex Ltd. has announced a 1-for-16 reverse split of its ordinary shares, which is scheduled to become effective on October 27, 2026.
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.